Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Floats 'Bold' Value-Based Reimbursement Idea In Migraine

Executive Summary

Novartis and Amgen are trying to build a compelling case for the value of their CGRP antagonist erenumab. Novartis said one strategy under consideration is to underwrite the cost of the drug for patients who don't respond.

Advertisement

Related Content

Novartis Aims Canakinumab At Targeted CV Patients
Novartis Back In AMD Game With ‘Potential Blockbuster’ Brolucizumab
Novartis's Entresto Voyage: Hindsight Is 20/20
Lilly Breathing Down Amgen/Novartis's Necks With Three Phase III Migraine Wins
Novartis On Payer Contracts, Other Updates From BIO CEO & Investor Conference

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099869

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel